Henry Scherb
Contact Résumé
01 · Life Sciences Strategy Consulting
Hayden Consulting Group · Consultant · 2024–present

I help biopharma leaders decide what to invest in, how to launch it, and where to take it next.

At Hayden, I've worked on 20+ strategic projects for mid-size biotech to large biopharma companies, covering acquisition diligence, launch strategy, forecasting and US/global expansion. Most of my work is in rare disease and CNS, where technical biology, small patient populations, complex reimbursement and high-stakes regulatory paths make the commercial case hardest to build.

20+Strategic projects
20+Indications across CNS, rare disease, oncology, pulmonary and hepatology
4Acquisition and investment diligence engagements
6Engagements leading or coaching junior team members
5Strategies presented to client executive leadership
2Promotions in two years

Trajectory and role

I was promoted twice and now own workstreams, timelines and client presentations, not just the analysis and internal alignment behind them.

  1. 2024Associate ConsultantPrimary and secondary research, models and client deliverables.
  2. 2025Senior Associate ConsultantOwned research and modeling workstreams end to end.
  3. 2026 · NowConsultantManage workstreams, timelines and client engagement; present to client leadership.

Leading teams and clients

  • Team leadership: led or coached junior team members on 6 engagements, including managing two analysts at once.
  • Executive presence: presented strategy to client executive leadership on 5 engagements.
  • Cross-functional alignment: ran client workshops and weekly meetings across medical, access, pricing, finance, legal, trade and brand teams.

Building the firm's Rare Disease Business Development Engine

I proposed, and now co-lead, Hayden's Rare Disease Committee: a business development engine that packages the firm's rare disease work into a center of excellence. I work directly with partners on BD strategy and help run pitches with large pharma and small to mid-size rare disease biotechs.

Selected work

Twelve engagements, grouped by the question each one answered. Client names are anonymized.

Acquisition and investment diligence

Should we buy or invest in this asset, and what is it really worth?
Private equity · Rare epilepsy, SMA

Mapping rare disease targets for a private equity investor

Portfolio diligence on acquisition and investment targets for an established life sciences PE firm entering rare epilepsy and SMA.

My role: Shaped the investment thesis with the client, then led the junior team building the investment model and target research.
Investor client · Deal economics

Pricing a royalty-sharing partnership

Modeled how contracting and marketing strategies could grow a marketed product's share, and what that meant for a royalty deal.

My role: Led the junior team through analog research, analytics and the model build; aligned Hayden partners, the client and our data team.
Outcome: Informed the investment decision on the partnership.
Mid-size biotech · PSC, PBC · M&A

Finding a new lead asset after a clinical failure

Commercial diligence on PSC and PBC assets to rebuild a hepatology portfolio after the client's lead asset failed.

My role: Built the model infrastructure and ran client working sessions so it fit how their teams would use it.
Outcome: Advised the client to acquire the recommended asset.
Mid-size pharma · Short bowel syndrome · M&A

Protecting a franchise ahead of patent expiry

Commercial diligence on the leading SBS pipeline candidate as the client's product neared patent expiry.

My role: Built the model infrastructure and drove alignment across the Hayden team.
Outcome: Supported the decision to acquire the candidate and expand the SBS pipeline.

Forecasting and market scenario modeling

What could this product earn, and what could knock it off course?
Pipeline asset · PAH, PH-ILD, IPF/PPF

Stress-testing a rare pulmonary launch

Simulated policy, competitor, payer and physician-adoption scenarios, alone and combined, grounded in physician and payer research.

My role: Coached a junior team member through the model build and led alignment in team meetings and client calls.
Outcome: Shaped launch pricing, indication sequencing and the playbook for competitor moves.
Oncology portfolio · Contracting

Winning access in consolidated oncology networks

Contracting and provider economics model for breast, pancreatic, ovarian and prostate cancer products in PE-owned, GPO-consolidated networks.

My role: Co-built the model with a new analyst and coached them to ownership, then pitched the strategy to Hayden partners.
Outcome: The client implemented our contracting strategy to improve late-lifecycle economics.
Leading MASH brand · Pricing strategy

Defending a liver disease brand against pricing pressure

Modeled PBM reform, GLP-1 and FGF21 competition, a list-price cut and a lower-priced second product.

My role: Built the model and presented it at a cross-functional client workshop spanning medical, access, pricing, finance, trade and brand.
Outcome: A strategic playbook with KPIs and an implementation plan for each market event.
Rare endocrine asset · CAH, Cushing's disease

Choosing which indication to launch first

Peak sales model comparing launch sequences, backed by payer and physician research on access barriers and competition.

My role: Built the model and led internal discussions to extend what it could do.
Outcome: Aligned on launching in CAH first, given higher unmet need and commercial upside.

Launch strategy and implementation

How do we get this product to patients and get it paid for?
Major pharma · Advanced Parkinson's disease

Bringing a drug-device combination to advanced Parkinson's patients

Modeled pricing, channel, trade and physician strategies for a launch made complex by its device component.

My role: Ran cross-functional education sessions, coached a junior team member, and presented the roadmap to the neurology portfolio's executive directors.
Outcome: A launch roadmap for a key growth product in the neurology portfolio.
Specialty pharma · IVF

Launching a novel fertility treatment end to end

Pricing, reimbursement, distribution, patient affordability and a cash-pay channel shaped by MFN and TrumpRx policies.

My role: Presented weekly to commercial, medical, legal, brand, access and trade teams and negotiated alignment across them.
Outcome: Launch is underway.
Novel hepatitis B therapy · Launch

Launching a hepatitis B treatment on a compressed timeline

Launch, reimbursement and patient experience strategy for a six-month weekly therapy, with approval and launch in the same year.

My role: Built the strategy playbook around the client's decision framework and presented it to the executive team.
Outcome: Now FDA approved and executing our strategy.
Global portfolio expansion · Respiratory portfolio and IBD monotherapy · 11 markets

Choosing where to launch outside the US

Commercial viability and forecasts across Europe, Japan and China, plus cash-pay markets including Brazil, Argentina, Saudi Arabia, Israel and India.

My role: Led the research, managed two junior team members, and presented the global strategy to executive leadership.
Outcome: Launch playbooks for viable markets, with risk milestones and bottlenecks mapped.

Therapeutic area experience

Rare neurology and CNSSMAMSAMSALSDMDParkinson's diseaseRare epilepsies
Rare endocrine and metabolicCAHCushing's diseaseMASH
Rare hepatology and GIPSCPBCHepatitis BShort bowel syndromeIBD
Rare pulmonaryPAHPH-ILDIPF/PPF
OncologyNon-small cell lungProstateOvarianPancreaticBreast
Women's health and respiratoryFertility and IVFGlobal respiratory portfolio